SPECIAL ISSUE - AGOlive Event: Prostate (Part1): Treatment of nmCRPC. Peculiarity of elderly patients
O.Caffo, S. Kinspergher, F. Maines, A. Veccia
Vol.6 (2021), issue 2, pag. 72 - 76
SPECIAL ISSUE - AGOlive Event: Prostate (Part1): Treatment of nmCRPC. Peculiarity of elderly patients
O.Caffo, S. Kinspergher, F. Maines, A. Veccia
Vol.6 (2021), issue 2, pag. 72 - 76
| Received | 23/08/2021 |
| Accepted | 1/09/2021 |
| Published | 07/09/2021 |
| Review by | Single-blind |
| DOI | https://doi.org/10.48253/AGO12 |
ABSTRACT
Three different new hormonal agents (apalutamide, darolutamide, enzalutamide) recently demonstrated an improvement in terms of both metastasis-free survival and overall survival of non-metastatic castration-resistant prostate cancer (nmCRPC). Since by de nition these patients, in absence of radiologically detectable metastases, are asymptomatic, the introduction of a new treatment requires a careful evaluation of risk to bene t ratio, mainly in elderly patients who are frail, have multiple comorbidities and takes several con- comitant drugs. This work explores the evidences about the ef cacy of NHAs in elderly nmCRPC patients, their toxicity pro le in this population and the potential drug-by-drug interactions with come- dications.